Envestnet Asset Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Envestnet Asset Management’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$234K	Buy	+4,448	New	+$198K	﹤0.01%	4570
2026 Q1	–	Sell	-12,625	Closed	-$487K	–	4713
2025 Q4	$487K	Buy	+12,625	New	+$429K	﹤0.01%	3718
2021 Q2	–	Sell	-9,508	Closed	-$488K	–	3636
2021 Q1	$488K	Buy	9,508 +590	+7%	+$32.3K	﹤0.01%	2858
2020 Q4	$442K	Sell	8,918 -3,566	-29%	-$160K	﹤0.01%	2722
2020 Q3	$487K	Buy	12,484 +1,539	+14%	+$62.7K	﹤0.01%	2477
2020 Q2	$473K	Buy	10,945 +1,020	+10%	+$39K	﹤0.01%	2461
2020 Q1	$291K	Buy	+9,925	New	+$342K	﹤0.01%	2563
2018 Q3	–	Sell	-206,663	Closed	-$6.75M	–	1363
2018 Q2	$6.75M	Buy	206,663 +143,611	+228%	+$4.72M	0.02%	413
2018 Q1	$1.98M	Buy	63,052 +62,714	+18,554%	+$2.05M	0.01%	713
2017 Q4	$10K	Buy	+338	New	+$9.46K	﹤0.01%	2623
2017 Q3	–	Sell	-338	Closed	-$8K	–	2917
2017 Q2	$8K	Hold	338	–	–	﹤0.01%	2741
2017 Q1	$8K	Hold	338	–	–	﹤0.01%	2815
2016 Q4	$6K	Buy	+338	New	+$6.74K	﹤0.01%	2839

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Envestnet Asset Management's BBC Position: Q2 2026 in Review

Envestnet Asset Management opened a new position in Virtus Biotech Clinical Trials ETF (BBC) in Q2 2026: 4,448 shares worth $234K. The stake represents ﹤0.01% of the portfolio and ranks #4570 among its holdings. This is a return to the name: Envestnet Asset Management previously reported a position in BBC as recently as Q4 2025.

Envestnet Asset Management first reported a position in BBC in Q4 2016 and has held it in 13 quarters since. The position peaked at $6.75M in Q2 2018. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

Envestnet Asset Management held 4,448 shares of Virtus Biotech Clinical Trials ETF worth $234K as of Q2 2026.
Virtus Biotech Clinical Trials ETF was a new Envestnet Asset Management position in Q2 2026.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4570 holding.
Envestnet Asset Management first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2016 and has held it in 13 quarters since.
Envestnet Asset Management's Virtus Biotech Clinical Trials ETF position peaked at $6.75M in Q2 2018.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.